GlassScriptPhysician profile
Rose D Soto
NPI 1376591099
$12,220.57
in general payments reported to CMS, 2019-2025
57 companies · $3,430 in 2025
The $3,430 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,698 · 2023: $2,243 · 2024: $3,951 · 2025: $3,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,429 · Travel and Lodging: $1,052 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,429.18 |
| Travel and Lodging | $1,051.89 |
| Education | $143.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,867.33 | 2021-2025 | |
| Abbott Laboratories | $1,649.66 | 2023-2025 | Infinity |
| Biogen, INC. | $688.01 | 2021-2025 | Skyclarys, Vumerity, Tysabri |
| Ucb, INC. | $656.66 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Pfizer INC. | $610.63 | 2023-2025 | |
| Emd Serono, INC. | $578.83 | 2022-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $388.45 | 2022-2025 | Ultomiris, Koselugo, Soliris |
| Lilly USA, LLC | $362.60 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $347.90 | 2021-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $310.41 | 2021-2025 | |
| Lundbeck LLC | $269.13 | 2023-2025 | Vyepti, Rexulti |
| Kyowa Kirin, INC. | $263.66 | 2021-2024 | Nourianz |
| Genentech USA, INC. | $247.95 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $234.10 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $219.87 | 2022-2025 | Rytary, Crexont |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $210.04 | 2023-2025 | |
| Argenx US, INC. | $202.47 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $193.47 | 2022-2023 | Austedo Xr |
| Eisai INC. | $192.43 | 2022-2025 | |
| Averitas Pharma INC. | $169.39 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $165.55 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $162.27 | 2023-2024 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $151.76 | 2021-2025 | Nuplazid |
| Amgen INC. | $147.24 | 2021-2025 | Uplizna, Aimovig |
| Mylan Specialty L.P. | $137.21 | 2023-2024 | Glatiramer Acetate |
| Biohaven Pharmaceuticals, INC. | $135.99 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.20 | 2022 | |
| Celgene Corporation | $122.57 | 2023-2025 | Zeposia |
| Medtronic, INC. | $111.83 | 2022-2023 | Graftonand Grafton Plusdemineralized Bone Matrix (Dbm), Atlantis Anterior Cervical Plate System |
| Jazz Pharmaceuticals INC. | $111.64 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $103.08 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $95.41 | 2023-2024 | Gocovri, Gocovri |
| Mallinckrodt Hospital Products INC. | $83.10 | 2022-2025 | Acthar |
| Merz Pharmaceuticals, LLC | $68.75 | 2025 | Xeomin, Ampyra, Inbrija |
| Supernus Pharmaceuticals, INC. | $68.16 | 2025 | Qelbree |
| Impel Pharmaceuticals LLC | $67.43 | 2025 | Trudhesa |
| Axsome Therapeutics, INC. | $61.42 | 2023-2024 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $56.84 | 2024-2025 | Hyqvia |
| Sk Life Science, INC. | $56.67 | 2022-2025 | Xcopri |
| Tanabe Pharma America, INC. | $52.68 | 2025 | Radicava |
| Ani Pharmaceuticals, INC. | $48.99 | 2023-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $41.87 | 2024-2025 | Wegovy |
| Neurelis, INC. | $40.39 | 2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $39.60 | 2024 | |
| Sunovion Pharmaceuticals INC. | $38.11 | 2022 | |
| Vanda Pharmaceuticals INC. | $34.35 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $31.27 | 2023 | Trudhesa |
| Avion Pharmaceuticals | $25.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.53 | 2025 | Keveyis |
| Banner Life Sciences, LLC | $24.03 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.88 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.70 | 2023 | Onpattro |
| Acorda Therapeutics, INC | $17.80 | 2023 | Ampyra, Inbrija |
| Avadel Cns Pharmaceuticals, LLC | $14.58 | 2024 | Lumryz |
| Collegium Pharmaceutical, INC. | $14.48 | 2022 | |
| Horizon Therapeutics Plc | $14.47 | 2023 | Uplizna |
| Arbor Pharmaceuticals, INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.